HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Macleods Pharmaceuticals Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Macleods Pharmaceuticals Intelligence Report

Generated from 10 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 73%

Evidence

60 items

Sources

9

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Macleods Pharmaceuticals maintains an active intelligence profile across Cardiovascular, Lipid Regulation, Endocrinology, Thyroid Disorders, Cardiology. 10 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 73% across 2 tracked sources. Highest-priority development: FDA TA — ANDA219207. Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Macleods Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA TA — ANDA219207

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — PROVOCHOLINE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — PROVOCHOLINE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — SODIUM BICARBONATE (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — LEVOTHYROXINE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — PADCEV (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 661 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA TA — ANDA219207

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PROVOCHOLINE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PROVOCHOLINE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SODIUM BICARBONATE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LEVOTHYROXINE SODIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PADCEV (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — ANDA220197

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves ANDA for Bupropion Hydrochloride by Macleods

    Neurology · Depression

  • FDA Grants Approval for Tofacitinib Citrate ANDA219530 by Macleods Pharmaceuticals

    Immunology · JAK Inhibitor

  • FDA Accepts ANDA for Choline Fenofibrate by Macleods Pharmaceuticals

    Cardiovascular · Lipid Regulation

  • FDA Grants AP Status for Levothyroxine Sodium ANDA211417

    Endocrinology · Thyroid Disorders

  • FDA Submission for Finerenone by Macleods Pharmaceuticals

    Cardiology · Mineralocorticoid Receptor Antagonist

  • FDA Grants AP Status for Levocetirizine Dihydrochloride ANDA205564

    Allergy · Antihistamine

  • FDA Grants Approval for Dapsone ANDA218335 by Macleods Pharmaceuticals

    Infectious Disease · Antimicrobial

  • FDA Grants Approval for Chlorthalidone ANDA212229 by Macleods Pharmaceuticals

    Cardiovascular · Diuretic

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.